Recon: Second patient death linked to Alzheimer’s drug lecanemab rocks Eisai, Biogen; Roche withdraws Tecentriq’s bladder cancer indication
Recon
BiologicsBiotechnologyDiagnosticsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy